Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesGilead Sciences Phase III Darusentan Data Show Significant Blood Pressure Reductions in Resistant Hypertension Patients
Gilead, 05/11/09
Gilead Sciences, Inc. announced the presentation of data from DAR-311, a Phase III clinical trial evaluating the company's once-daily oral endothelin receptor antagonist darusentan as an add-on treatment for resistant hypertension, defined as the failure to achieve goal blood pressure while adhering to full doses of an appropriate three-drug regimen that includes a diuretic. The data are being presented during an oral late-breaker session at the American Society of Hypertension, Inc. Twenty-Fourth Annual Scientific Meeting and Exposition in San Francisco.
Today in Cardiac/Hypertension...keeping you current
Receive free subspecialty "5-minute updates" via email
Reduction of blood pressure in patients with treatment-resistant hypertension
Expert Opinion in Pharmacotherapy, 12/09/09
Non-adherence to statin therapy: a major challenge for preventive cardiology
Expert Opinion in Pharmacotherapy, 12/08/09
Pioglitazone and mechanisms of CV protection
QJM: An International Journal of Medicine, 12/08/09
Today in Drug Resistance...keeping you current
Receive free subspecialty "5-minute updates" via email
Reduction of blood pressure in patients with treatment-resistant hypertension
Expert Opinion in Pharmacotherapy, 12/09/09
Linezolid in the Treatment of Multidrug-Resistant Tuberculosis
Clinical Infectious Diseases, 12/08/09
Efficacy and Safety of Efalizumab in Patients with Moderate-to-Severe Plaque Psoriasis Resistant to Previous Anti-Psoriatic Treatment: Results of a Multicentre, Open-label, Phase IIIb/IV Trial
Archives of Drug Information, 12/08/09
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors
Journal of Clinical Oncology, 12/09/09
Umbilical vein oxytocin for the treatment of retained placenta (Release Study): a double-blind, randomised controlled trial
The Lancet - Early Online Publication, 12/09/09
The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury
Trials, 12/09/09
Sponsor
Article Search
Sponsor